MetaCap

Lycia Therapeutics (LYCA) vs Recursion Pharmaceuticals (RXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.53 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LYCA+10.23%RXRX-33.78%
+20%-8%-36%
Oct 23, 20261 yearNov 20, 2026
LYCA+10.23%RXRX-33.78%
+12%-12%-36%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LYCA versus RXRX key metrics
MetricLYCARXRX
Share price$33.07$2.45
Market cap$1.72B$1.53B
1-day change+4.09%-9.93%
YTD return—-40.10%
1-year return—-41.25%
5-year return—-87.04%
EPS (TTM)$-1.04$-0.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$74.68M
Revenue growth (YoY)—+26.92%
Net income (latest FY)—$-644.76M
Gross margin—4.99%
Operating margin—-867.87%
Net margin—-863.35%
52-week high$36.49$5.24
52-week low$22.19$2.44
Distance from 52-week high-9.37%-53.24%
Analyst consensus—buy
Avg. price target upside—+176.33%
Average volume432.72K24.47M
Shares outstanding52.09M622.76M
Employees31600
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

LYCA vs RXRX FAQ

Which is bigger, Lycia Therapeutics or Recursion Pharmaceuticals?

Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.53B for Recursion Pharmaceuticals (RXRX).

Are Lycia Therapeutics and Recursion Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons